NOT DISCLOSED, California
| Asking Price |
$11,500,000 |
Year Established |
2018 |
|
| Annual Revenue |
$9,951,000 |
Reason for Selling |
Focus on other business |
|
| Annual P/L |
$0 |
Attention |
Tyler Le |
|
| Annual Cash Flow |
$2,167,000 |
Listing Number |
1015878 |
|
| # of Employees |
13 |
Business Category |
Retail: Health, Beauty, Nutrition |
|
Business Overview:
Highly profitable two-location independent retail pharmacy operating in Orange County and San Bernardino County, California. TTM revenue of $9.95M with $2.17M Adjusted EBITDA (21.8% margin) — independently validated by Plante & Moran, PLLC, a top-15 U.S. CPA firm, as part of a formal Quality of Earnings review. +37% YoY Adjusted EBITDA growth.Both locations are INSIDE medical office buildings — 6 of the top 10 prescribers practice in the SAME building as our pharmacies. Regional hospital is steps away with shared parking (Orange County). Modern VPN-enabled technology stack for multi-store and enterprise management (PioneerRx PMS, Parata robotic dispensing, Parata Perl verification, AlignRx PSAO, 2D barcode scanning). Business has implemented an AI Automation bot to process prescriptions 24/7 at a fraction of the labor cost. Owner is not active in day-to-day operations; both Pharmacists-in-Charge are long-tenured and highly likely to remain post-close.Growth catalysts in flight: drive-through expansion under construction at one location (permits pulled, ground broken), 470+ ALF beds in advanced LTC pipeline discussions, Medicare Part B DMEPOS billing infrastructure and Medicare Part B Mass Immunizer active. None of this upside is credited in the listed price — it is available to the buyer.Transaction: Structured as a Stock Sale (negotiable) at $11,500,000 listed. Real estate leased at both locations (assumable). 1–6 month flexible transition. Full Plante & Moran QoE workbook released post-IOI.
Property Features and Assets:
<p>Two leased retail pharmacy suites, each inside a medical office building (~2,000-2,200 SF per location). Both leases assumable at close.<br></p>
Market Competition and Expansion:
<p>* Chain Retreat Creates Demand: CVS, Walgreens, and Rite Aid have closed 2,000+ U.S. stores since 2023. Well-positioned independents are recapturing displaced demand — particularly in the medical-office-embedded submarkets these pharmacies occupy.<br><br>* Physician-Adjacency Moat: 6 of top 10 prescribers practice in the SAME building as our pharmacies — geographic, sticky, and expensive to replicate in the same submarket.<br><br>* Third-Party QoE (Plante & Moran): QoE-validated financials are rare at this size — materially strengthens buyer confidence and compresses diligence time.<br><br>* Modern Multi-Store Tech Stack: PioneerRx PMS, Parata robotic dispensing + Perl verification, AlignRx PSAO, 2D barcode scanning — designed for multi-store enterprise management, VPN-enabled across sites, and includes VOPIX and shared PBX phone system integrated with PioneerRx for click to call, fax, and ability to use vendor apps in case of power outage.<br><br>* AI Automation Bot: 24/7 automated Rx processing at a fraction of human tech labor cost — differentiated cost structure in an industry where labor is the largest opex line.<br><br>* Growing LTC Market: Southern California ALF bed supply is growing faster than LTC pharmacy capacity.<br><br>* 3-License Expansion / Drive-Through Flagship: New drive-through retail flagship location under construction — permits pulled, ground broken. Buyer inherits committed CapEx. This new location will share the building with an urgent care and primary care physician office.<br><br>* LTC Pipeline (470+ Beds): 470+ ALF beds in advanced discussion — to be serviced by existing comboshop operations (both Chino Plaza and Anaheim carry dual NPI/NCPDP for retail + LTC). Currently servicing 4 LTC facilities (Anaheim Villa, Esperanza's Place I & II, JNJ II Maple) at ~3,298 Rxs / ~$183K revenue LTM without formal contracts — validates operational LTC capability.<br><br>* AI Automation Bots — Multi-Site Rollout: Bots deployed at both locations and very scalable. Both locations will be able to expand volume without any additional staff.<br><br>* Medicare Part B DMEPOS: Diabetic Supplies (855-S) approved July 2026 at one location; Mass Immunizer (855-B) active at both sites. Additional DMEPOS categories available.<br><br>* Additional Levers: MTM, RPM, 340B contract pharmacy (with nearby FQHC), expanded immunization outreach, compounding (greenfield), and structured B2B delivery — all documented, none activated.<br></p>
Additional Details:
- The property is Leased.
- The owner is willing to train/assist the new owner.
- This is not homebased business opportunity.
- This is not a franchise resale opportunity